Combination of PDT and a DNA demethylating agent produces anti-tumor immune response in a mouse tumor model

Epigenetic mechanisms, which involve DNA methylation and histone modifications, result in the heritable silencing of genes without a change in their coding sequence. However, these changes must be actively maintained after each cell division rendering them a promising target for pharmacologic inhibition. DNA methyltransferase inhibitors like 5-aza-deoxycytidine (5-aza-dC) induce and/or up-regulate the expression of MAGE-type antigens in human and mice cancer cells. Photodynamic therapy (PDT) has been shown to be an effective locally ablative anti-cancer treatment that has the additional advantage of stimulating tumor-directed immune response. We studied the effects of a new therapy that combined the demethylating agent 5-aza-dC with PDT in the breast cancer model 4T1 syngenic to immunocompetent BALB/c mice. PDT was used as a locally ablating tumor treatment that is capable of eliciting strong and tumor directed immune response while 5-aza-dC pretreatment was used promote de novo induction of the expression of P1A.protein. This is the mouse homolog of human MAGE family antigens and is reported to function as a tumor rejection antigen in certain mouse tumors. This strategy led to an increase in PDT-mediated immune response and better treatment outcome. These results strongly suggest that the MAGE family antigens are important target for PDT mediated immune response but that their expression can be silenced by epigenetic mechanisms. Therefore the possibility that PDT can be combined with epigenetic strategies to elicit anti-tumor immunity in MAGE-positive tumor models is highly clinically significant and should be studied in detail.

[1]  Mladen Korbelik,et al.  Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. , 2005, Cancer research.

[2]  M. Korbelik,et al.  Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. , 1999, Cancer research.

[3]  T. Tomasi,et al.  Epigenetic regulation of immune escape genes in cancer , 2006, Cancer Immunology, Immunotherapy.

[4]  Barbara W Henderson,et al.  Generation of effective antitumor vaccines using photodynamic therapy. , 2002, Cancer research.

[5]  T. Tomasi,et al.  Histone deacetylase regulation of immune gene expression in tumor cells , 2008, Immunologic research.

[6]  B. Seliger,et al.  5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[8]  T. Foster,et al.  Activation of Heat Shock Protein 70 Promoter with meso-Tetrahydroxyphenyl Chlorin Photodynamic Therapy Reported by Green Fluorescent Protein In Vitro and In Vivo¶ , 2003 .

[9]  A. Cincotta,et al.  Role of the Immune System in Mediating the Antitumor Effect of Benzophenothiazine Photodynamic Therapy , 1999, Photochemistry and photobiology.

[10]  H. S. de Bruijn,et al.  Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. , 1996, Cancer research.

[11]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[12]  B. McManus,et al.  Nuclear factor-kappaB activation by the photochemotherapeutic agent verteporfin. , 2000, Blood.

[13]  O. de Backer,et al.  The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Frank Lyko,et al.  DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy. , 2004, Trends in pharmacological sciences.

[15]  Adrian Bird,et al.  The essentials of DNA methylation , 1992, Cell.

[16]  S. Tweedie,et al.  The methyl-CpG binding domain and the evolving role of DNA methylation in animals. , 2003, Trends in genetics : TIG.

[17]  F. Garrido,et al.  Rexpression of HLA class I antigens and restoration of antigen‐specific CTL response in melanoma cells following 5‐aza‐2′‐deoxycytidine treatment , 2001, International journal of cancer.

[18]  Michael R Hamblin,et al.  Mechanisms in photodynamic therapy: part two-cellular signaling, cell metabolism and modes of cell death. , 2005, Photodiagnosis and photodynamic therapy.

[19]  M. Korbelik,et al.  Neutrophils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumours , 2002, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[20]  Paola Taroni,et al.  Antitumor immunity induced by photodynamic therapy with aluminum disulfonated phthalocyanines and laser light , 1994, Anti-cancer drugs.

[21]  C. Uyttenhove,et al.  The shared tumor‐specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection , 1998, European journal of immunology.

[22]  C. Benz,et al.  Clinical development of histone deacetylase inhibitors as anticancer agents. , 2005, Annual review of pharmacology and toxicology.

[23]  Michael R Hamblin,et al.  Mechanisms in photodynamic therapy: Part three-Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. , 2005, Photodiagnosis and photodynamic therapy.

[24]  T. Tomasi,et al.  Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells , 2008, Cancer Immunology, Immunotherapy.

[25]  Peter A. Jones,et al.  Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.

[26]  C J Gomer,et al.  Photodynamic therapy-mediated oxidative stress can induce expression of heat shock proteins. , 1996, Cancer research.

[27]  A. Melcher,et al.  Apoptosis or necrosis for tumor immunotherapy: what's in a name? , 1999, Journal of Molecular Medicine.

[28]  F. Lyko,et al.  DNA Methyltransferase Inhibitors for Cancer Therapy , 2007, Cancer journal.

[29]  Vera Rogiers,et al.  Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. , 2004, Current medicinal chemistry.

[30]  M. Korbelik,et al.  Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy. , 1995, British Journal of Cancer.

[31]  Michael R Hamblin,et al.  Photodynamic therapy and anti-tumour immunity , 2006, Nature Reviews Cancer.

[32]  J. Herman,et al.  Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours , 2002, The Journal of pathology.

[33]  J. Krosl,et al.  The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. , 1996, Cancer research.

[34]  M. Korbelik,et al.  Characteristics of complement activation in mice bearing Lewis lung carcinomas treated by photodynamic therapy. , 2005, Cancer letters.

[35]  H. Cedar,et al.  Role of DNA methylation in the regulation of transcription. , 1994, Current opinion in genetics & development.

[36]  A. Goetz,et al.  Strong and prolonged induction of c-jun and c-fos proto-oncogenes by photodynamic therapy. , 1996, British Journal of Cancer.

[37]  Michael R Hamblin,et al.  Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. , 2004, Photodiagnosis and photodynamic therapy.

[38]  K. Irvine,et al.  De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. , 2006, Cancer research.

[39]  J. Yewdell,et al.  Identification of human cancers deficient in antigen processing , 1993, The Journal of experimental medicine.

[40]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[41]  R. Voll,et al.  Immunosuppressive effects of apoptotic cells , 1997, Nature.